# metabolic dysfunction-associated steatohepatitis (MASH) - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: liver tissue
- Comparison or endpoint: MASH/NASH versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: f634f84e95c290ce4195eb13604b114b4c86ce8adb76238e59c436c955ac43b9
- Response HTTP status: 200
- Prompt tokens: 31665
- Completion tokens: 11409
- Reasoning tokens: 0
- Total tokens: 43074
- API requests reported: 2
- Elapsed seconds: 137.566
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1019.869
- Question handoff seconds: 1032.938
- Final benchmark system: E2seq; file rank 2/5; original repeat 2; model vendor: OpenAI

---
## Data-quality and evidence scope

The uploaded table contains **100 unique genes** and **101 retained rows**, with **one duplicated gene/probe entry for CAST**. The ledger reports **51 upregulated and 49 downregulated genes**, and all 100 unique genes meet **FDR ≤ 0.01**. This is an unusually saturated result distribution: every selected feature is highly significant, while the table provides no sample size, effect-size uncertainty, batch information, or independent cohort statistic. Therefore, the **directions and log2FC values are the direct evidence**, but biological interpretation should remain cautious about possible technical, compositional, or selection effects.

The duplicate CAST record is also flagged as having a **direction conflict** in the ledger, although the displayed representative is **upregulated, log2FC=4.0158444, P=2.4782075e-10, FDR=7.0161895e-08**. CAST should therefore not be treated as a fully resolved directional marker without returning to the underlying probe-level data. No prognostic HR analysis is present.

The broad interpretation is that MASH liver differs from healthy liver through a combination of:

1. **Remodeling of hepatic macrophage populations**, with strong loss of resident Kupffer-cell markers and induction of TREM2-associated, lipid-handling or activated macrophage features.
2. **Immune and stress signaling**, including marked induction of CXCL10, UBD, TNFRSF12A, TP53I3, and DUSP8.
3. **Altered mitochondrial, redox, and lipid-associated metabolism**, involving UQCRBP1, CYCS, FABP5, GGTLC1, CBS, SCLY, and MTHFD1L.
4. **Changes in vascular, lymphatic, adhesion, and extracellular-interface genes**, including reduced CDH5, VCAM1, LYVE1, PCDH20, and TIMD4.
5. **A possible regenerative or proliferative response**, supported by FOXM1 and EME1, but not sufficient to establish hepatocyte proliferation without cell-type-resolved data.

These findings are biologically compatible with MASH, but **external statistical validation was not performed**. Pathway, interaction, tissue, and literature records are contextual evidence rather than replication.

## Core biological programs

### 1. Hepatic macrophage-state remodeling and altered efferocytosis

- **Direction:** Mixed state transition rather than uniformly increased or decreased macrophage activity.
- **Supporting genes:**  
  - Downregulated: **TIMD4, MARCO, CD163, MRC1, FOLR2, CR1, CSF1R, CD5L, SIGLEC1, SPIC, CD209, MPEG1, P2RY13, LYVE1**.  
  - Upregulated: **TREM2, FABP5, CAPG**.
- **Relevant standardized terms:**  
  - GO: **phagocytosis**, **efferocytosis**, **receptor-mediated endocytosis**, **immune-cell activation**.  
  - Reactome: **regulation of complement cascade** and related innate immune processes.  
  - The supplied literature includes an MASH biomarker study focused on **efferocytosis-related biomarkers**: PubMed **PMID: 39497821**.
- **Interpretation:** The coordinated reduction of resident Kupffer-cell and sinusoidal macrophage markers—particularly TIMD4, MARCO, CD163, MRC1, FOLR2, and CSF1R—combined with strong TREM2 induction (**log2FC=4.9112589**) and increased FABP5 (**2.8489194**) is more consistent with **macrophage compartment remodeling** than with a simple increase in total macrophage abundance. One plausible model is depletion or transcriptional displacement of homeostatic resident Kupffer cells and increased representation of recruited or disease-associated lipid-handling macrophages.
- **Evidence strength:** **Strong direct transcriptomic pattern**, because many related genes change coherently. External pathway and literature records support plausibility, but not independent replication.
- **Limitations:** Bulk liver expression cannot distinguish loss of resident macrophage cells from phenotype switching. TREM2 induction does not by itself establish pathogenic macrophage function, and the apparently opposing behavior of TREM2 versus resident markers may reflect cell composition rather than intracellular reprogramming.

### 2. Innate immune, interferon-associated, and tissue-injury signaling

- **Direction:** Predominantly upregulated inflammatory/stress signaling, with simultaneous reduction of several complement-regulatory or myeloid-interface genes.
- **Supporting genes:** **CXCL10** upregulated (**3.4625204**), **UBD** upregulated (**4.1513847**), **TNFRSF12A** upregulated (**3.2708061**), **TP53I3** upregulated (**3.2613395**), **DUSP8** upregulated (**3.4942373**), and **TSC22D1** upregulated (**1.4546321**). **CR1**, **CFP**, and **CD209** are downregulated.
- **Relevant standardized terms:**  
  - Hallmark: **Interferon Gamma Response** and **Inflammatory Response**, as candidate annotations rather than formally calculated enrichment.  
  - Reactome: **regulation of complement cascade** and cytokine/immune signaling.
- **Interpretation:** CXCL10 is compatible with interferon-responsive immune recruitment, while UBD, TNFRSF12A, TP53I3, and DUSP8 suggest cellular stress, inflammatory signaling, and altered stress-kinase feedback. The reduction of CR1 and CFP points to altered complement-interface biology, but it does not demonstrate reduced complement activity in the tissue.
- **Evidence strength:** **Moderate to strong direct evidence** for an immune/stress-associated transcriptional state because several genes converge on this theme. CR1 has external complement annotations and STRING associations with C3, C4A, C4B, MBL2, and CFI, but these are external functional or interaction records rather than cohort statistics.
- **Limitations:** CXCL10 can arise from several immune and parenchymal cell types. No cytokine measurements, phosphoproteomics, or histological evidence are available, so pathway activity and causal inflammatory signaling remain **supported hypotheses**.

### 3. Mitochondrial, redox, and lipid-handling adaptation

- **Direction:** Mixed metabolic adaptation, with induction of mitochondrial/stress-associated and lipid-handling genes alongside suppression of selected metabolic genes.
- **Supporting genes:** Upregulated **UQCRBP1** (**3.7327884**), **CYCS** (**1.5645424**), **FABP5** (**2.8489194**), **GGTLC1** (**2.3338117**), **MTHFD1L** (**1.717158**), and **MANF** (**1.8542216**); downregulated **CBS** (**-1.2539373**), **SCLY** (**-1.2821056**), and **CETP** (**-2.4871225**).
- **Relevant standardized terms:**  
  - GO: **glutathione catabolic process** and **glutathione gamma-glutamate hydrolase activity** for GGTLC1.  
  - Reactome: candidate **mitochondrial electron transport** and one-carbon/metabolic processes.  
  - KEGG: the supplied batch returned **aminoacyl-tRNA biosynthesis**, but this is not sufficient to claim a coherent MASH metabolic enrichment, particularly because formal enrichment statistics were not supplied.
- **Interpretation:** The pattern suggests altered mitochondrial electron-transfer capacity, oxidative-stress handling, lipid trafficking, and one-carbon metabolism. GGTLC1 upregulation is compatible with altered glutathione turnover, whereas FABP5 may reflect increased intracellular lipid handling in macrophages or other hepatic cells. The opposite directions of CBS, SCLY, and CETP suggest that this is not a globally activated metabolic program but a **redistributed or cell-type-specific metabolic state**.
- **Evidence strength:** **Moderate direct evidence**, supported by multiple genes and relevant GO annotations. It is not evidence of increased or decreased total oxidative phosphorylation because no gene-set statistic or functional assay was provided.
- **Limitations:** Several metabolic genes may be driven by altered cellular composition. Transcript abundance does not establish metabolite flux, redox state, mitochondrial respiration, or lipid accumulation.

### 4. Vascular, lymphatic, adhesion, and extracellular-interface remodeling

- **Direction:** Predominantly downregulated.
- **Supporting genes:** **VCAM1** (**-2.3779684**), **CDH5** (**-1.3761514**), **LYVE1** (**-2.7298689**), **PCDH20** (**-4.5928013**), **TIMD4** (**-4.2820453**), **TINAGL1** (**-1.7770147**), and **P4HA1** (**-3.1945022**). **DTNA** is strongly upregulated (**3.7233096**).
- **Relevant standardized terms:**  
  - GO: **cell-cell adhesion via plasma-membrane adhesion molecules (GO:0098742)**, returned in the supplied annotation batch.  
  - GO/Reactome: candidate vascular endothelial junction and extracellular-matrix organization processes.
- **Interpretation:** The decrease in CDH5, LYVE1, VCAM1, and P4HA1 is compatible with changes in sinusoidal endothelial, lymphatic, adhesion, or matrix-associated compartments. However, the direction does not support a simple claim of generalized endothelial activation or fibrosis. The concurrent downregulation of several resident macrophage and endothelial-associated markers raises the possibility of **loss or altered representation of sinusoidal cell populations** in bulk tissue.
- **Evidence strength:** **Moderate direct evidence** for altered tissue-interface composition or state; pathway annotation supports biological plausibility.
- **Limitations:** P4HA1 downregulation is not a canonical bulk signature of increased collagen hydroxylation, so these results should not be interpreted as evidence against fibrosis or as evidence of a specific fibrosis stage. Histology and cell-type-resolved data are needed.

### 5. Regeneration, cell-cycle, and cellular stress response

- **Direction:** Predominantly upregulated.
- **Supporting genes:** **FOXM1** (**2.143543**), **EME1** (**1.880170**), **TP53I3** (**3.2613395**), **AJUBA** (**1.9207037**), **TSC22D1** (**1.4546321**), **MANF** (**1.8542216**), and **MTRNR2L8** (**3.2546741**).
- **Relevant standardized terms:** Candidate Hallmark **G2M Checkpoint**, **E2F Targets**, and **p53 Pathway**, but no formal Hallmark enrichment result was supplied.
- **Interpretation:** FOXM1 and EME1 together are compatible with cell-cycle entry, DNA-repair activity, or regenerative remodeling. TP53I3 and MANF support a cellular stress-response interpretation. This could reflect hepatocyte regeneration, proliferating nonparenchymal cells, or an altered mixture of liver cell populations.
- **Evidence strength:** **Exploratory to moderate direct evidence**; the multi-gene pattern is more informative than FOXM1 alone, but the evidence is not cell-type specific.
- **Limitations:** No proliferation marker panel, cell-cycle score, Ki-67 staining, or single-cell data is available. The program should not be described as established hepatocyte proliferation.

## Key genes and interaction modules

| Candidate | Current dataset | Role and relationship type |
|---|---:|---|
| **TREM2** | Up, log2FC **4.9112589**, FDR **3.8985146e-09** | Strong candidate marker of a disease-associated lipid-handling macrophage state. Its relationship with **CSF1R** is represented in OmniPath/ConnectomeDB as a network or regulatory association, not a demonstrated direct physical interaction in this dataset. |
| **TIMD4–MARCO–CD163–MRC1–FOLR2 module** | Down: TIMD4 **-4.2820453**, MARCO **-2.8438665**, CD163 **-2.5174854**, MRC1 **-2.1018504**, FOLR2 **-2.0396177** | Coherent resident Kupffer-cell/homeostatic macrophage signature. These genes are pathway co-membership and cell-state markers; their joint decrease may indicate composition change. It is not evidence that they physically interact with one another. |
| **TREM2–FABP5–CAPG module** | TREM2 **+4.9112589**, FABP5 **+2.8489194**, CAPG **+2.5668182** | Putative disease-associated macrophage/lipid-handling module. The relationship is primarily indirect or pathway/state co-membership; direct physical interaction is not established by the supplied evidence. |
| **CD163–MRC1–SIGLEC1 network** | All down: CD163 **-2.5174854**, MRC1 **-2.1018504**, SIGLEC1 **-2.1177135** | STRING reports a functional network connection. This should be called a **network association**, not a direct protein complex or causal regulatory circuit. |
| **MARCO–CD36–CD163 network** | MARCO **-2.8438665**, CD163 **-2.5174854**; CD36 is not among the uploaded genes | STRING provides external functional associations involving CD36, MARCO, and CD163. Because CD36 is not statistically measured in this table, this is contextual evidence only. |
| **CXCL10** | Up, log2FC **3.4625204**, FDR **1.1833082e-07** | Candidate interferon-associated inflammatory biomarker or recruitment signal. Its relationship to immune activation is regulatory/functional and indirect; no direct interaction with the other selected genes is established. |
| **CR1–complement interface** | CR1 down, log2FC **-3.6086216**, FDR **2.1126244e-09** | CR1 has Reactome and QuickGO complement annotations and STRING associations with C3, C4A, C4B, MBL2, and CFI. These include protein-level complement relationships, but complement activity itself was not measured. |
| **UQCRBP1–CYCS mitochondrial module** | UQCRBP1 **+3.7327884**, CYCS **+1.5645424** | Compatible with altered mitochondrial electron-transfer or stress biology. This is pathway co-membership, not proof of a direct UQCRBP1–CYCS interaction or increased respiratory function. |
| **GGTLC1–glutathione module** | GGTLC1 up, log2FC **2.3338117**, FDR **2.0374648e-08** | GO supports glutathione catabolic activity; STRING links GGTLC1 with GGT1, GGT6, GSTA1, and GSS. These are enzyme-network/pathway associations, not evidence that all listed proteins physically bind. |
| **FOXM1–EME1 regenerative module** | FOXM1 **+2.143543**, EME1 **+1.880170** | Compatible with cell-cycle and DNA-repair activity. The relationship is functional/pathway-level; no direct physical interaction is asserted. |

## Validation priorities

### 1. Resolve macrophage composition versus macrophage state

- **Class:** Confounding or composition check; also a mechanistic hypothesis.
- **Why prioritize it:** The strongest coherent signal is the opposing behavior of resident macrophage markers and TREM2/FABP5/CAPG.
- **Current evidence:** TIMD4, MARCO, CD163, MRC1, FOLR2, CSF1R, CR1, and SIGLEC1 are downregulated, whereas TREM2, FABP5, and CAPG are upregulated.
- **External evidence:** The supplied Reactome, QuickGO, STRING, and MASH efferocytosis literature record support macrophage and complement relevance, including PMID **39497821**, but do not provide independent cohort statistics.
- **Next step:** Single-cell or single-nucleus RNA-seq, spatial transcriptomics, or multiplex immunohistochemistry for TIMD4, MARCO, CD163, FOLR2, TREM2, FABP5, and CSF1R, together with macrophage cell counts.
- **Classification:** The differential pattern is **established evidence in this dataset**; the interpretation as resident-cell loss plus TREM2-positive replacement is a **supported hypothesis**.

### 2. Test the CXCL10-centered inflammatory state

- **Class:** Mechanistic hypothesis and biomarker.
- **Why prioritize it:** CXCL10 is strongly induced and may identify an interferon-associated inflammatory component of MASH.
- **Current evidence:** CXCL10 log2FC **3.4625204**, FDR **1.1833082e-07**, with supporting induction of UBD, TNFRSF12A, TP53I3, and DUSP8.
- **External evidence:** Literature and pathway annotations support CXCL10 as an immune signaling mediator, but the retrieved literature records supplied here do not constitute replication of this exact result.
- **Next step:** Measure CXCL10 protein in liver and plasma, assess interferon-response genes in cell-resolved data, and relate the signal to histological inflammation and fibrosis scores.
- **Classification:** **Supported hypothesis**, not established causal inflammation.

### 3. Verify mitochondrial and glutathione functional consequences

- **Class:** Mechanistic hypothesis.
- **Why prioritize it:** MASH involves metabolic and oxidative stress, and the dataset contains coordinated changes in mitochondrial, glutathione, lipid-handling, and one-carbon genes.
- **Current evidence:** UQCRBP1, CYCS, GGTLC1, FABP5, MTHFD1L, and MANF are upregulated, while CBS and SCLY are downregulated.
- **External evidence:** GO annotations support GGTLC1 involvement in glutathione catabolism and STRING records place it in a glutathione-related enzyme network. These are plausibility evidence, not measurements of flux.
- **Next step:** Quantify hepatic glutathione redox ratios, lipid species, oxidative-damage markers, mitochondrial respiration, and protein abundance in independent MASH and control samples.
- **Classification:** **Exploratory to supported hypothesis**, depending on confirmation at the protein and metabolite levels.

### 4. Validate tissue-interface and vascular-cell remodeling

- **Class:** Confounding or composition check; interaction/network hypothesis.
- **Why prioritize it:** Downregulation of CDH5, LYVE1, VCAM1, PCDH20, and P4HA1 could represent endothelial/lymphatic remodeling or altered cell abundance.
- **Current evidence:** Multiple interface-associated genes are downregulated, and GO:0098742 was returned in the supplied annotation batch.
- **External evidence:** Ontology and tissue-expression resources make the cell-type interpretation plausible, but no independent cohort statistic or histological validation is available.
- **Next step:** Use endothelial and lymphatic markers in spatial profiling or immunostaining, and compare expression after computational deconvolution or cell sorting.
- **Classification:** **Supported hypothesis** for altered tissue-interface biology; the precise mechanism is **exploratory**.

### 5. Assess FOXM1-associated regeneration without assuming proliferation

- **Class:** Mechanistic hypothesis.
- **Why prioritize it:** FOXM1 and EME1 are jointly induced, but the biological source is uncertain.
- **Current evidence:** FOXM1 log2FC **2.143543** and EME1 log2FC **1.880170**, accompanied by TP53I3 and stress-response genes.
- **External evidence:** The pattern is compatible with cell-cycle and DNA-repair programs, but no cell-type-resolved or histological evidence is supplied.
- **Next step:** Quantify Ki-67, phospho-histone H3, DNA-replication markers, and cell-type-specific FOXM1 expression; test whether the signal correlates with hepatocyte injury and regeneration.
- **Classification:** **Exploratory hypothesis**. It should not currently be considered evidence that FOXM1 is a therapeutic target in MASH.

## Limitations and alternative explanations

1. **Cell-composition effects are likely important.** Bulk liver measurements can produce large apparent changes when Kupffer, endothelial, lymphatic, stellate, or infiltrating immune-cell proportions differ. Deconvolution, single-cell profiling, spatial assays, and cell-count-normalized expression are needed.

2. **The significance distribution is technically unusual.** All 100 genes have FDR ≤ 0.01, and no sample-level diagnostics are provided. Possible contributors include strong biological separation, preselected features, batch effects, leakage in feature selection, or an underestimated variance model. Reanalysis should include sample-level PCA, quality control, batch covariates, replicate structure, and volcano/MA plots.

3. **No formal enrichment statistics are available.** The supplied GO, KEGG, Reactome, and STRING results are annotations or network records. They do not establish enrichment, pathway activation, or replication. In particular, KEGG terms such as tuberculosis or malaria can arise from shared innate-immune genes and should not be interpreted as those infections being present.

4. **Disease heterogeneity is unresolved.** MASH severity, fibrosis stage, obesity, diabetes, medication exposure, age, sex, and inflammation can all influence these signatures. Clinical metadata and stratified analyses are required.

5. **Association does not establish causality.** The data identify disease-associated transcriptional states, not causal drivers or effective treatments. Drug-target records, where available, should guide experimental prioritization only after target engagement, disease-relevant perturbation, toxicity, and efficacy are independently demonstrated.

Overall, the most defensible interpretation is a **MASH-associated remodeling of hepatic macrophage and tissue-interface compartments, accompanied by inflammatory stress and metabolic adaptation**, with TREM2, the resident-macrophage marker module, CXCL10, CR1/complement biology, and GGTLC1–mitochondrial/redox signals as high-priority validation targets.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=4, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 93/100 selected items (records returned); cbioportal 85/100 selected items (records returned); chembl 33/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 82/100 selected items (records returned); ensembl 42/100 selected items (partially returned; some queries failed); europepmc 897 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 75/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 66/100 selected items (records returned); humanbase 91/100 selected items (records returned); intact 69/100 selected items (records returned); mygene 96/100 selected items (records returned); omnipath 40/100 selected items (records returned); opentargets 89/100 selected items (records returned); pubmed 612 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 69/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 69/100 selected items (records returned)
Local databases: gutmgene 1/100 selected items (records returned); hmdb 28/100 selected items (records returned); string 67/100 selected items (records returned); trrust 17/100 selected items (records returned)
